Aspira Pathlab & Diagnostics Ltd

Key board approvals and financial disclosures

• Unaudited standalone Q1 FY2026-27 results approved; revenue 616.91 lakh, total income 628.85 lakh.
• Net loss for Q1: Rs 3.77 lakh; basic/diluted EPS -0.04.
• Auditors expressed unmodified opinion on the results.
• Internal Auditor appointed: M/s Harsh Kholiya & Co for Q2–Q4 FY2026-27.
• Vaibhav Odhekar appointed Additional Executive Director from 12 Aug 2026, subject to shareholders' approval.
• Regularize Vaibhav Odhekar as Executive Director subject to shareholders' approval.
• Nikunj Velji Mange redesignated as Managing Director from 12 Aug 2026, subject to AGM approval.
• Board decided not to pursue fund-raising at this meeting.
• Directors Vaibhav Odhekar and Nikunj Velji Mange are not debarred from holding office.
• Authorised signing of unaudited standalone results by Nikunj Mange.
• Integrated filing for quarter ended 30 June 2026 filed.

Meeting Details

• Board meeting scheduled for August 12, 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026.
• Proposal to raise funds via preferential issue/private placements/rights issue or other methods, subject to approvals.
• To transact other incidental and ancillary matters as may be decided by the board.

Other Notes

• Notice of Board Meeting to be uploaded on the company website.

Resignation details

• Vaibhav Odhekar, Additional Executive Director (Executive), resigns.
• Reason: personal reasons.
• Date of cessation: close of business on July 25, 2026.

Dematerialisation status and listing

• Securities received for dematerialisation were processed and confirmed to depositories.
• Securities dematerialised have been listed on the exchanges where the earlier issues are listed.
• Physical certificates received were mutilated and cancelled; depository name substituted as registered owner within timelines.